Health consequences of sexually transmitted diseases disproportionately affect women, making it important to determine whether newly emerged pathogens cause sequelae. Although the pathogenic role of Mycoplasma genitalium in male urethritis is clear, fewer studies have been conducted among women to determine its pathogenic role in the female reproductive tract. Pelvic inflammatory disease (PID) is an important cause of infertility and ectopic pregnancy, and Chlamydia trachomatis and Neisseria gonorrhoeae are recognized microbial causes. Emerging data demonstrate an association between M. genitalium and PID, and limited data suggest associations with infertility and preterm birth, yet the attributable risk for female genital tract infections remains to be defined. Further investigations are needed to better define the impact of M. genitalium on women's reproductive health. Importantly, prospective studies evaluating whether screening programs and targeted treatment of M. genitalium improve reproductive outcomes in women are necessary to guide public health policy for this emerging pathogen.
Mycoplasma genitalium was first detected in 2 men with nongonococcal urethritis [1] , and subsequent studies linking M. genitalium with male urethritis have been remarkably consistent. Today, M. genitalium is widely accepted as a cause of male urethritis [2] , and key issues related to M. genitalium infection in men are summarized in the article by Horner and Martin in this issue [3] . Sexual transmission between men and women is highlighted by studies demonstrating concordance of M. genitalium infection status in sex partners (summarized in [4] ) and by multilocus genotyping demonstrating identical genotypes in 87% of concurrently infected sex partners [5] . Despite this, many fewer studies of M. genitalium have been conducted in women, data documenting morbidity are less consistent than in men, and associations with female reproductive tract disease syndromes are of lower magnitude. Nevertheless, because women are at risk of the most significant adverse consequences of reproductive tract infections [6] , decisions to invest in disease control programs are often based on the strength of the evidence in women.
A recent meta-analysis summarized the literature on M. genitalium infection in women and reported an approximately 2-fold increased risk of cervicitis, pelvic inflammatory disease, preterm delivery, spontaneous abortion, and infertility that was statistically significant for all but infertility [7] . Nevertheless, questions remain over the importance of M. genitalium and female reproductive tract disease syndromes. Although the evidence for disease associations between M. genitalium and female clinical syndromes has grown substantially in the last decade, it remains imperfect. Given the time and resources required to design and conduct the epidemiologic studies needed to complete that evidence base, identifying key gaps in our knowledge and prioritizing the most important questions are critical. Therefore, we undertook a critical evaluation of the evidence with the goal of summarizing the strength of the evidence base and identifying priorities for future research. We began with the literature identified after a comprehensive search of the literature for a recent meta-analysis, on which one of us was a coauthor [7] . We then searched PubMed for papers published between 25 June 2014 (the last date of the search for the meta-analysis) and 31 December 2016 using a single search term: Mycoplasma genitalium.
Lower Genital Tract Infection
Cervicitis was initially described >30 years ago as "the ignored counterpart of urethritis in men" [8] , most likely because the 2 syndromes share known etiologies. However, cervicitis differs from male urethritis in that low-grade signs of infection more often go unnoticed, in part due to the need for a speculum exam to observe these. The clinical diagnosis is also subjective and often inaccurate, and this is evident in studies of M. genitalium and cervicitis. Definitions of cervicitis ranged widely across these studies, and include visible mucopurulent cervical discharge [9] ; objective evidence of inflammation, defined as ≥10, ≥20, or ≥30 polymorphonuclear leukocytes per highpower field (PMN/HPF) [10] [11] [12] (with or without mucopurulent discharge); easily induced cervical bleeding [13] ; and more PMNs than epithelial cells [14] .
Individual studies evaluating the association of M. genitalium and cervicitis have produced mixed results with respect to statistical significance, but nearly all (n = 18/21) have demonstrated an increase in risk. Effect sizes in most studies are relatively modest, however, suggesting that fairly large sample sizes are needed to detect a statistically significant effect. Despite the heterogeneity across studies, M. genitalium was significantly associated with a 70% increase in risk of cervicitis (odds ratio [OR] = 1.7; 95% CI = 1.35-2.04) per a recent meta-analysis [7] ( Figure 1 ).
Notwithstanding this evidence from meta-analysis, nearly all studies of cervicitis have been cross-sectional in nature. Prospective studies demonstrating that cervicitis followed the acquisition of M. genitalium would provide more definitive evidence, but these studies are challenging to conduct. However, in vitro and animal models help elucidate mechanisms for pathogenesis in the lower reproductive tract. Mycoplasma genitalium is capable of infecting mucosal cells in the marmoset female genital tract and a prolonged inflammatory response resulted in the lower genital tract after inoculation [15] . Acute M. genitalium infection of endocervical cells causes destruction of microvilli and an increase in secretory vesicle formation [16] . Mycoplasma genitalium infection of endocervical cells in vitro also elicited a proinflammatory cytokine and chemokine response with secretion of interleukin 6, interleukin 7, interleukin 8, monocyte chemotactic protein 1, and granulocyte-macrophage colony stimulating factor [17] . Proinflammatory cytokine levels are high in women with chronic M. genitalium infection, raising speculation that, similar to untreated chlamydial infections, persistent M. genitalium infection may be deleterious to the female reproductive tract due to resultant chronic inflammation [18] [12] , and several showing no association [22] [23] [24] . A recent longitudinal study suggested that susceptibility to M. genitalium may be enhanced in the presence of BV [25] in a manner similar to that described for Neisseria gonorrhoeae and Chlamydia trachomatis. Mycoplasma genitalium alone, however, does not appear to be a cause of vaginitis.
Studies from Sweden and Norway have demonstrated a relationship between M. genitalium and female urethritis, although the magnitude varies based on how urethritis is defined. When defined as clinical symptoms of dysuria or urgency, M. genitalium was associated with a statistically significant 3-fold increase in risk [26] , whereas the risk was 2-fold higher when urethritis was defined as ≥4 PMN/HPF on microscopic examination of a methylene blue-stained urethral smear [27, 28] . These studies suggest that M. genitalium can cause female urethritis, but the body of evidence is small.
Pelvic Inflammatory Disease
Pelvic inflammatory disease (PID) is typically a polymicrobial syndrome of the female upper genital tract, including endometritis, salpingitis, pelvic peritonitis, and tuboovarian abscess, and is an important cause of infertility in women. Historically, PID was considered to be primarily caused by either Chlamydia trachomatis or Neisseria gonorrhoeae. However, the majority of women with PID are not infected with either of these 2 STD pathogens; rather, anaerobic and facultative organisms are more frequently isolated from the upper genital tract in women with acute PID [29] .
A slowly growing body of literature is examining whether there is an association between Mycoplasma genitalium and [7] . Abbreviation: CI, confidence interval.
PID. Early studies examining M. genitalium serologic responses had conflicting results, partly due to insufficiently sensitive and specific serologic assays and potentially reflecting current uncertainty over the role of serologic testing in the detection of PID and/or its consequences. Among 31 patients with acute PID, approximately 40% had increasing titers of M. genitalium antibodies as measured by microimmunofluorescence, consistent with a recent M. genitalium infection as the etiologic agent [30] . However, Jurstrand et al demonstrated similar rates of seropositivity to M. genitalium in women with acute PID and in pregnant women, consistent with no association [31] . The development of nucleic acid amplification testing (NAAT) in research settings enabled further investigation, demonstrating that M. genitalium can be detected in the upper genital tract of women with acute PID. Among women at a Kenyan STD clinic presenting with acute pelvic pain, M. genitalium was identified by polymerase chain reaction (PCR) in the endometrium in 12% (n = 7/58) of women with histologic endometritis, whereas it was not present in the endometrium of women without endometritis [32] . Moreover, the prevalence of M. genitalium in the endometrium in women with endometritis was similar to that of N. gonorrhoeae (10%) and C. trachomatis (7%). Simms et al identified M. genitalium by PCR on cervical swabs in 13% (n = 6/45) of women clinically diagnosed with acute PID, whereas none of the 37 control women tested positive [33] . In a United States-based PID treatment trial, 15% of women were infected with M. genitalium, and infection was associated with histologic endometritis [34] . Results from such studies using NAAT constitute the bulk of the evidence summarized in the meta-analysis, which yielded a 2-fold increase in risk of PID across studies [7] (Figure 1 ).
Most women with infertility due to fallopian tube damage do not have a history of acute PID but are more commonly seropositive for C. trachomatis or N. gonorrhoeae than women without infertility [35] . Similarly, an association between M. genitalium seropositivity and tubal factor infertility has been observed, independent of past chlamydial infection [36] . These observations suggest that subclinical or unrecognized infections, which may be more common than acute PID, may cause reproductive harm [37] . Subclinical PID (histologic endometritis in the absence of signs or symptoms of acute PID) is often present in women with uncomplicated chlamydial or gonococcal cervicitis or bacterial vaginosis [38] . Among 558 women at an urban STD clinic who did not have acute PID, subclinical PID was identified in 22 of 43 (51%) women infected with M. genitalium, similar to the rate of 47% in those testing positive for C. trachomatis. When controlling for chlamydia, gonorrhea, and bacterial vaginosis, cervical M. genitalium infection was independently associated with subclinical PID (adjusted odds ratio [aOR] = 2.4; 95% confidence interval [CI] = 1.2-4.6), [39] . Similar to acute PID, a prospective study has demonstrated that women with subclinical PID are at risk for infertility [40] . The role and extent of M. genitalium in subclinical disease, as well as acute pelvic infection, warrant further study.
Although most studies support an association between Mycoplasma genitalium and acute PID, the importance of antimicrobial eradication of this organism has not been determined. Doxycycline and azithromycin are often used as components of antimicrobial therapy for PID, yet the efficacy of doxycycline to treat M. genitalium cervicitis is poor, and resistance to macrolides is an emerging concern [41] . Standard treatment consisting of cefoxitin and doxycycline failed to eradicate M. genitalium in 41% of women with acute PID [34] . Although short-term treatment failures (defined as histologic evidence of endometritis and pelvic pain) were more common in women with M. genitalium in this study, the clinical efficacy of PID regimens that include Centers for Disease Control and Prevention-recommended regimens is high [42] . For these reasons, studies of both the short-term clinical efficacy and longterm reproductive outcomes of PID regimens in women with M. genitalium are urgently needed.
Screening and treatment of women with Chlamydia trachomatis has been associated with a reduced incidence of PID [43] . A similar relationship with M. genitalium would corroborate its pathogenic role in PID. Oakeshott et al performed a secondary analysis of a trial of chlamydia screening to prevent PID, testing stored samples for M. genitalium [19] . Women infected with M. genitalium had a 2-fold higher incidence of PID over 12 months compared with uninfected women, a difference that did not achieve statistical significance (3.9% vs 1.7%; relative risk = 2.35; 95% CI = .74-7.46; P = .14). These results, coupled with the low prevalence of M. genitalium (3.3%) in their cohort, led the authors to conclude that M. genitalium was not a major causative agent of PID. However, the study population consisted of relatively low-risk women, and PID was initially identified by self-reported symptoms up to 1 year after the M. genitalium infection was detected, reducing the sensitivity of the study. Further studies of M. genitalium screening, particularly in communities where M. genitalium is prevalent, are necessary to understand the true risk of PID among infected women.
Sequelae of Upper Genital Tract Infection: Infertility and Ectopic

Pregnancy
Approximately 25% of infertility is due to tubal occlusion and is often referred to as tubal factor infertility (TFI). This is known to occur after upper tract infection with C. trachomatis or N. gonorrhoeae [44, 45] , and the risk of infertility increases with additional episodes of chlamydial infection [46] . In vitro and animal studies are exploring the effect of M. genitalium infection on the fallopian tube mucosa. Microscopic evidence of ciliary damage was demonstrated in human fallopian tube explants infected with M. genitalium, albeit the damage was more moderate than that seen with C. trachomatis or N. gonorrhoeae infection [47] (Figure 2) . A pig-tailed macaque model has been explored to characterize ascension of M. genitalium and its pathogenesis in upper genital tract infection [48] . When studied in a model using auto-transplanted salpingeal pockets implanted in the animal's anterior abdominal wall, M. genitalium was present for up to 2 weeks [49] . However, when examined for ascending infection after cervical inoculation, none of the 6 primates with persistent lower genital tract infection had evidence of M. genitalium infection in the fallopian tubes. Although M. genitalium can cause upper genital tract inflammation, additional studies are needed to further elucidate the pathogenesis of M. genitalium in the female reproductive tract. Studies should include animal models and should investigate whether recurrent M. genitalium infections are associated with a higher risk of sequelae in the same manner as recurrent chlamydial infections.
Epidemiologic studies of infertility are difficult to conduct, in part due to the multifactorial etiology, and in part because the relative importance of a current versus a prior infection is unknown. If damage occurs soon after active infection, detecting the organism may demonstrate associations. If the greatest risk occurs after damage caused by an immune response to infection, detecting circulating antibody by serology may reveal associations. Both direct detection and serology have been used to assess the relationship between M. genitalium and infertility, but there are no consistent trends in results based on type of assay. Although epidemiologic data are somewhat mixed, on balance they suggest that the risk of infertility is elevated in women who have experienced M. genitalium infections. Serologic studies have produced conflicting results, due in part to suboptimal sensitivity and specificity of current serologic assays. Additionally, the characterization of the immune response to urogenital infection with M. genitalium and the significance of serologic assays are not well defined. The earliest serologic study using a first-generation seroassay observed a nonsignificant decrease in risk [50] , but 2 subsequent serologic studies that adjusted for antibodies to C. trachomatis reported statistically significant 4.5-5.5-fold increased risks of infertility [36, 51] . In contrast, the most recent serologic study among women in Sweden, which also adjusted for the presence of antibodies to chlamydia, found no significant association with TFI and M. genitalium [52] . Results from studies using NAAT to detect the organism in the reproductive tract have been similarly mixed. The largest study, which tested endometrial specimens from US women with clinically diagnosed PID, reported a modest and nonsignificant 40% increase in the risk of infertility after adjusting for chlamydia, gonorrhea, and infertility at baseline [34] . In contrast, a case-control study in Poland detected M. genitalium by NAAT testing of cervical and peritoneal specimens and showed a 5-fold increase in risk of infertility, although investigators did not adjust for chlamydial or gonococcal infection [53] . Despite the heterogeneity in studies of infertility, in meta-analysis, the approximately 2-fold increase in risk approached statistical significance (OR = 2.4; 95% CI = 0.93-6.34); Figure 1 ) and increased when restricted to studies that accounted for chlamydial and gonococcal infection (OR = 3.3; 95% CI =1.23-8.57) [7] .
Interpreting studies of M. genitalium and infertility is complicated by the populations studied and the methods used to determine infertility. Comparison groups of women at high risk of infertility for other reasons may mask any effect of M. genitalium. For example, in the most recent Swedish serologic study, women with TFI were compared with women with other causes of infertility, yet M. genitalium was strongly associated with anycause fertility. The comparison with fertile women, which may have yielded different results, was not reported [52] . Similarly in the large study of US women, all women had clinically diagnosed PID, and all were at elevated risk of infertility, which may have muted any effect of M. genitalium [34] .
Ectopic pregnancy can result from damaged cilia and has been strongly linked to upper tract infection with N. gonorrhoeae and C. trachomatis [35] . The ciliary damage observed in fallopian tube tissue suggests that this can also occur with M. genitalium infection (Figure 2 ) [47] , but there is a paucity of epidemiologic studies; only 2 studies appear in the published literature and each used different diagnostic methods to detect M. genitalium. When serum specimens from 82 Swedish women with ectopic pregnancies and 246 healthy pregnant women screened for rubella were tested for the presence of M. genitalium antibodies, the association was modest, not statistically significant, and disappeared after adjustment for C. trachomatis (aOR = 1.0; 95% CI = .5-2.0) [31] . In contrast, when NAAT testing for M. genitalium was performed on tubal tissue from 84 hospitalized Saudi women with ectopic pregnancies undergoing salpingectomy and 51 women undergoing hysterectomy or tubal ligation, detection of M. genitalium was significantly associated with ectopic pregnancy, even after adjustment for other pathogens (aOR = 2.3; 95% CI = 1.1-8.6) [54] . Elucidating the role of M. genitalium in both infertility and ectopic pregnancy requires a better understanding of the etiologically relevant time period from infection to adverse outcome, more accurate definitions of infertility and ectopic pregnancy, a thorough characterization of the immune response to urogenital M. genitalium infection, and better serologic assays.
Adverse Pregnancy Outcomes
Preterm delivery, defined as delivery of an infant before 37 weeks of gestation, occurs in approximately 13% of US women [55] . The etiology of preterm delivery is multifactorial, with infectious etiologies accounting for 25%-30% of these deliveries [56] . Studies of preterm birth and M. genitalium have included a mix of case-control and cohort studies, yet many had small numbers of women with preterm delivery or M. genitalium infection or both, limiting statistical power. In 2 studies, the prevalence of M. genitalium was <1%, and M. genitalium was not detected in any of the women with preterm birth [57, 58] . Individual studies have reported an increased risk of preterm delivery, ranging from a nonsignificant 30% increase among low-risk women attending a community health center [59] to a 2.5-fold increase in risk among Peruvian women presenting with spontaneous labor in a maternity hospital [60] . Although the nearly 2-fold increased risk of preterm delivery in meta-analysis (OR = 1.9; 95% CI = 1.25-2.85) (Figure 1 ) is lower than the 5-6-fold increase associated with syphilis and gonorrhea [61] , it is higher than the 40%-80% increase associated with T. vaginalis and BV [62, 63] and may warrant intervention. However, the relatively low prevalence of M. genitalium in the populations studied to date argues against universal screening of pregnant women. Whether a targeted strategy testing women at high risk of M. genitalium could prevent preterm birth requires prospective clinical trials.
Many of the studies of preterm delivery also evaluated spontaneous abortion or miscarriage. This is also multifactorial and not always clinically evident, challenging our ability to determine the role of M. genitalium. Additionally, the current body of evidence is characterized by a wide diversity of risk and prevalence of M. genitalium in populations studied, heterogeneous methods of defining the outcomes, and potentially low statistical power. Definitions of spontaneous abortion ranged from documented events in a hospital setting to self-report of pregnancies without live births. Many of these studies reported increased risk of spontaneous abortion/miscarriage among women with M. genitalium, although only 1 was statistically significant. Effect estimates range from a nonsignificant 50% increase in risk (OR = 1.5; 95% CI = .03-16.4) among low-risk women attending a community health center [59] to a statistically significant 2-fold elevation in risk (aOR = 2.3; 95% CI = 1.04-4.88) among Ugandan women engaged in commercial sex work [20] . Although 2 studies reported inverse relationships, ranging from 0.6 in a large study of West African women to 0.9 among adolescent girls and women attending an emergency department [64, 65] , neither of these was statistically significant. Despite this substantial heterogeneity, the meta-analysis demonstrated a statistically significant 80% increase in risk (OR = 1.8; 95% CI = 1.10-3.03) (Figure 1 ) [7] . Similar to research priorities for preterm delivery, longitudinal studies of high-risk cohorts of women in populations that have a high prevalence of M. genitalium are needed to determine relationships between M. genitalium and spontaneous abortion.
SUMMARY AND CONCLUSION
Associations between M. genitalium and most female reproductive tract syndromes have been demonstrated, and, although the statistical significance of study results is not always uniform, a relatively consistent picture across studies has emerged. As with many sexually transmitted pathogens, the strength of the relationships with reproductive tract syndromes is lower in women than in men. Furthermore, the pace of research evaluating the role of M. genitalium in reproductive tract disease syndromes has been slower in women than in men, in part because studies in women are more difficult to conduct, and the sequelae (including PID and infertility) are often challenging to identify. Nevertheless, fairly consistent evidence shows that women with M. genitalium are at increased risk of PID, infertility, and adverse pregnancy outcomes and it is probably an important pathogen. However, additional data will be required before routine screening can be recommended. We have summarized research priorities in Table 1 . 3. Identification of the extent of immune activation in the genital tract, as well as predictors and consequences of immune activation.
4. Estimation of the attributable risk of M. genitalium infection for adverse reproductive health sequelae in women (eg, pelvic inflammatory disease, spontaneous abortion, preterm delivery, infertility, and ectopic pregnancy).
5. Determination of whether screening women for M. genitalium reduces the incidence of adverse sequelae, including pelvic inflammatory disease, spontaneous abortion, preterm delivery, infertility, and ectopic pregnancy.
Key among these research priorities is identifying the attributable risk for reproductive tract syndromes in women. Determining how often M. genitalium infections result in PID, infertility, and adverse pregnancy outcomes is a necessary prerequisite to determining the public health importance of M. genitalium infection. We currently lack the prospective studies that are necessary to determine this. Prospective studies are also necessary to clearly demonstrate causal relationships, particularly with respect to PID and infertility. Perhaps most important is the lack of clinical trials to determine whether detecting and treating M. genitalium infections can prevent adverse sequelae such as PID, infertility, and adverse pregnancy outcomes. Such data will be necessary to accurately judge the extent to which M. genitalium impacts women's health and the extent to which control programs would be cost effective. Conducting these studies will require a fairly significant investment in time and resources, yet this investment is essential to ensure that healthcare providers have the information they need to make clinical decisions for women seeking reproductive health care and to give public health and regulatory agencies the data needed to determine whether systematic prevention and control programs are needed.
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